Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15014579 | 0.84 | TLR9 (0.39) | TLR9TLR8TLR7MAPTRECQL | |
| SCHEMBL12727215 | 0.82 | MAPT (0.40) | TLR9TLR8TLR7MAPTRECQL | |
| SCHEMBL12424320 | 0.82 | TLR9 (0.38) | TLR9TLR8TLR7MAPTRECQL | |
| SCHEMBL12384701 | 0.81 | DRD2 (0.37) | GRIN2BGRIN1 | |
| SCHEMBL12384858 | 0.79 | MAPT (0.41) | TLR9TLR8TLR7MAPTRECQL | |
| SCHEMBL12384610 | 0.78 | CNR2 (0.39) | MAPTKDM4E | |
| SCHEMBL15214318 | 0.77 | L3MBTL1 (0.46) | TLR9TLR8TLR7MAPTRECQL | |
| SCHEMBL24491587 | 0.76 | MAPT (0.43) | TLR9TLR8TLR7MAPTRECQL | |
| SCHEMBL14375262 | 0.74 | KDM4E (0.51) | TLR9TLR8TLR7MAPTRECQL | |
| SCHEMBL15468520 | 0.74 | TLR9 (0.41) | TLR9TLR8TLR7MAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | TLR9 2536/4885TLR8 2407/4885TLR7 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.